Administration of calcimimetics after dialysis: Same effectiveness, better gastrointestinal tolerability

• Published in: Nefrología 2015-07, Vol.35 (4), p.403-409
• Main Authors: Esteve Simo, Vicent, Moreno-Guzmán, Fátima, Martínez Calvo, Gemma, Fulquet Nicolas, Miquel, Pou Potau, Monica, Macias-Toro, Javier, Duarte-Gallego, Verónica, Saurina Sole, Anna, Ramírez-de Arellano Serna, Manel
• Format: Article
• Language: English
• Subjects: Calcimimetics; Haemodialysis; Secondary hyperparathyroidism
• ISSN: 2013-2514
• DOI: 10.1016/j.nefroe.2015.09.002

Introduction: Cinacalcet has proved effective to control secondary hyperparathyroidism in patients on haemodialysis (HD). Some studies have reported an appropriate secondary hyperparathyroidism control and a better compliance after intradialytic use of calcimimetics. Objectives: To assess the effect of post-dialysis calcimimetics use on mineral bone disorders and calcimimetics gastrointestinal tolerability in our HD unit. Material and methods: A 12-week single-centre prospective study in HD patients treated with cinacalcet (>2 months). Two study periods: usual outpatient use (Stage 1) and use after HD session (Stage 2). Endpoints: (1) biochemical MBD data; (2) Gastrointestinal Symptom Rating Scale (GSRS) for gastrointestinal tolerability, and visual analogic scale (VAS) for satisfaction; (3) adherence: Morisky–Green test (MG) and final tablet count (TC). Results: Sixty-two HD patients. Fourteen received cinacalcet (22.5%). TEN patients were included, mean age was 60.9 years; patients had received HD for 80.9 months. Mean Charlson index: 9. Biochemical data: Stage 1 (initial vs. final): Ca 8.8 ± 0.5 mg/dl vs. 9.1 ± 0.7 mg/dl (P